CNTRP researchers James Shapiro and Kirk Schultz inducted as fellows into the Canadian Academy of He
CNTRP researchers James Shapiro and Kirk Schultz were inducted as fellows into the Canadian Academy of Health Sciences during a ceremony in Ottawa on September 17, 2015.
Dr. Schultz and Dr. Shapiro, with fellow CAHS member Dr. Lori West, at the CAHS Inauguration Ceremony in Ottawa on Sept 17, 2015.
The Canadian Academy of Health Sciences (CAHS) provides timely, informed and unbiased assessments of urgent issues affecting the health of Canadians. Fellows elected to the Academy are recognized by their peers nationally and internationally for their contributions to the promotion of health science. Election to Fellowship in the Academy is considered one of the highest honours for individuals in the Canadian health sciences community and carries with it a covenant to serve the Academy and the future well being of the health sciences irrespective of the Fellow’s specific discipline.
On behalf of the CNTRP, we offer our congratulations to Dr Shapiro and Dr. Schultz for this well deserved recognition.
Andrew Mark James Shapiro, University of Alberta
Invigorated the field of islet transplantation by leading the team that developed the Edmonton Protocol, an islet transplantation technique considered worldwide as a major advancement for managing severe Type 1 diabetes. He continues his translational research, managing the largest islet transplant program in the world. His work has provided insight into, and furthered our understanding of, immune tolerance. Current efforts include leading Canada-wide research to improve organ procurement through emerging ex vivo perfusion technology. This technology holds the promise of significantly improving the rate of organ utilization and graft function. James Shapiro is lead of the CNTRP Project 1 on Ex vivo organ transplant protection and repair
Kirk Schultz, University of British Columbia
Dr. Kirk Schultz is a Professor at the University of British Columbia, BC Children’s Hospital, and the Child and Family research Institute (CFRI). Dr. Schultz is a Pediatric Hematologist/Oncologist focused on new therapies and rejection in Blood and Marrow Transplantation (BMT) and immune therapy of blood cancers. Dr. Schultz is a past recipient of the CIHR/Wyeth Clinical Research Chair in Transplantation and past chair of the Pediatric BMT Consortium the largest children’s BMT clinical trials group in the world. He is currently the director of the Michael Cuccione Childhood Cancer Research Program group at the BC Children’s Hospital and CFRI. Kirk Schultz is the lead of the CNTRP Research infrastructure and registries support platform (Core 2)